Key Takeaways A higher-than-anticipated report on consumer inflation sent U.S. equities lower at midday.Solar power company ...

Analysts upgraded shares of the healthcare company to Overweight from Equal Weight and raised their price target to $82.

CVS Health (CVS) stock gained as Barclays upgraded the company, citing a compelling path to margin recovery in its Medicare ...

CVS Health (CVS – Research Report) received a Buy rating and an $82.00 price target from Barclays analyst Andrew Mok CFA today. The ...

Barclays upgrades CVS Health to Overweight, citing gains in pharmacy market share and potential upside from CostVantage. CVS is expected to recover 200 basis points in Medicare margins by 2026, ...

Barclays upgraded CVS Health Corp (NYSE: CVS) shares to Overweight from Equal Weight, citing a promising outlook for the ...

Barclays analyst Andrew Mok CFA maintained a Hold rating on CVS Health (CVS – Research Report) today and set a price target of $63.00.

The drugstore chain's board has hired bankers to help review options for the company, including a potential breakup. Shares ...

CVS Health (CVS) has lost ~22% in value this year ... the move will likely be an overhang for the stock in the near term. Barclays analyst Stephanie Davis disagreed. “However, we believe the ...

CVS, Considering a Breakup, Will Find It's Hard to Do Splitting the healthcare company into stand-alone pharmacy or health insurance ... Worry About iPhone Demand. Barclays analyst Tim Long ...

Advt Cigna announced last month that it would remove Humira from some of its lists in 2025, following similar action by CVS Health's Caremark ... quarter of this year, Barclays analysts said ...